Pharmaceutical company perspectives on current safety risk communications in Japan

SpringerPlus

Volumn 3, Issue 1, 2014, Pages 1-11

  Urushihara, Hisashi ^a   Kobashi, Gen ^b   Masuda, Hideaki ^c   Taneichi, Setsuko ^d   Yamamoto, Michiko ^e   Nakayama, Takeo ^f   Kawakami, Koji ^f   Matsuda, Tsutomu ^g   Ohta, Kaori ^h   Sugimori, Hiroki ⁱ  

^a KEIO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^c Dentsu Public Relations Inc   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^f KYOTO UNIVERSITY   (Japan)

^g YAMAGATA UNIVERSITY   (Japan)

^h NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

ⁱ DAITO BUNKA UNIVERSITY   (Japan)

Author keywords

Drug company; Drug risk; Questionnaire survey; Regulation; Safety communication

Indexed keywords

EID: 84897801778     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-3-51     Document Type: Article

References (34)

1. Avorn J (2008) Drug warnings that can cause fits-communicating risks in a data-poor environment. N Engl J Med 359(10):991-994. doi:10.1056/NEJMp0805922.
2. Bahri P (2010) Public Pharmacovigilance Communication A Process Calling for Evidence-Based, Objective-Driven Strategies. Drug Saf 33(12):1065-1079. doi:10.2165/11539040-000000000-00000.
3. Bahri P, Harrison-Woolrych M (2012a) Focusing on Risk Communication About Medicines: Why Now? [Editorial]. Drug Saf 35(11):971-975.
4. Bahri P, Harrison-Woolrych M (2012b) How to Improve Communication for the Safe Use of Medicines? Discussions on Social Marketing and Patient-Tailored Approaches at the Annual Meetings of the WHO Programme for International Drug Monitoring. Drug Saf 35(12):1073-1079.
5. Committee on Regulatory Restructuring for Inspection and Recurrence Prevention of Drug-Induced Hepatitis Disaster Case (2010) The Final Recommendation on Restructuring Drug Regulatory Administration for Drug Disaster Prevention [in Japanese]. General Affairs Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare, Tokyo.
6. Committee on Safety of Medicines (2005) Always Read the Leaflet, Getting the best information with every medicine. Report of the Committee on Safety of Medicines Working Group on Patient Information. Medicines and Healthcare products Regulatory Agency, London.
7. Czarnecki A (2008) Intelligent risk communication: can it be improved? Drug Saf 31(1):1-6.
8. Davis JJ, Cross E, Crowley J (2007) Pharmaceutical websites and the communication of risk information. J Health Commun 12(1):29-39. doi:10.1080/10810730601091326.
9. Edwards B, Chakraborty S (2012) Risk Communication and the Pharmaceutical Industry: What is the Reality? [Article]. Drug Saf 35(11):1027-1040.
10. European Medicines Agency (2009) Information on Benefit-risk Balance of Medicines: Patients', Consumers' and Healthcare Professionals' Expectations. EMEA/40926/2009.
11. European Medicines Agency, London European Medicines Agency (2013) Guideline on Good Pharmacovigilance Practices (GVP), Module XV-Safety Communication. EMA/118465/2012.
12. Giampaolo V (2010) Erice Statement 2009: communication, medicines and patient safety. Br J Clin Pharmacol 69(2):207-208. doi:10.1111/j.1365-2125.2009.03562.x.
13. Horiuchi T, Isobe T, Takagi H, Tsutani K, Katahira N, Matsushita K (2009) Interim Report: Research on Inspection and Recurrence Prevention of Drug-Induced Hepatitis Disaster Case, Sponsored by the H20 Research Grant from the Ministry of Health Labor and Welfare for Medicines and Medical Devices Regulatory Science Multidisciplinary Research Project. Research Group on Inspection and Recurrence Prevention of Drug-Induced Hepatitis Disaster Case, Tokyo.
14. Ingate S, Tranter D, Banerjee A, Hobbs A (2006) An Industry Perspective on the Erice Declaration and Risk Minimisation Plans. Drug Saf 29:733.
15. Japan Pharmaceutical Manufacturers Association (2013) JPMA website, Member Companies. [in Japanese]. http://www.jpma.or.jp/english/. Accessed March 14.
16. Kim H (2011) Pharmaceutical companies as a source of health information: a pilot study of the effects of source, web site interactivity, and involvement. Health Market Quarter 28(1):57-85. doi:10.1080/07359683.2011.545327.
17. Kimberlin CL, Winterstein AG (2008) Expert and Consumer Evaluation of Consumer Medication Information-2008. U.S. Department of Health and Human Services and the Food and Drug Administration.
18. Mazor KM, Andrade SE, Auger J, Fish L, Gurwitz JH (2005) Communicating safety information to physicians: an examination of dear doctor letters. Pharmacoepidemiol Drug Saf 14(12):869-875. doi:10.1002/pds.1102.
19. Mebane FE (2005) The importance of news media in pharmaceutical risk communication: proceedings of a workshop. Pharmacoepidemiol Drug Saf 14(5):297-306. doi:10.1002/pds.993.
20. Media Doctor Australia (2012) The Media Doctor. http://www.mediadoctor.org.au/. Accessed July 27 2012.
21. Olsen AK, Whalen MD (2009) Public Perceptions of the Pharmaceutical Industry and Drug Safety. Drug Saf 32(10):805-810.
22. Pharmaceuticals and Food Safety Bureau (2005) On Preparation Standards of the Drug Guide for Patients [in Japanese]. Yaku-shoku Hatsu No. 063001. Ministry of Health, Labour and Welfare, Tokyo.
23. Pharmaceuticals and Food Safety Bureau (2011a) On guidance of provision of emergency safety information, etc. [in Japanese]. Yaku-shoku-an Hatsu No. 0715-1. Ministry of Health, Labour and Welfare, Tokyo.
24. Pharmaceuticals and Food Safety Bureau (2011b) On provision of drug safety information [in Japanese]. Yaku-shoku-an Hatsu No. 0715-3. Ministry of Health, Labour and Welfare, Tokyo.
25. Pharmaceuticals and Food Safety Bureau (2012) Guidance of Risk Management Planning for Pharmaceuticals [in Japanese]. Yaku-shoku-an Hatsu 0411 No.1, Yaku-shoku-shinsa Hatsu 0411 No.2. Ministry of Health, Labour and Welfare, Tokyo.
26. Raynor DK, Svarstad B, Knapp P, Aslani P, Rogers MB, Koo M, Krass I, Silcock J (2007) Consumer medication information in the United States, Europe, and Australia: a comparative evaluation. J Am Pharm Assoc (2003) 47(6):717-724. doi:10.1331/JAPhA.2007.06141.
27. Seligman PJ, Osborne SF (2009) Perspectives on early communication of drug risks to the public. Clin Pharmacol Ther 85 (3):335-339. doi:10.1038/clpt.2008.272.
28. Suka M (ed) (2011) Results of Questionnaire Survey on Provision of Drug Information to Patients [in Japanese]. Summary Research Report of the Science of Health Labor and Welfare for Medicines and Medical Devices Regulatory Science Multidisciplinary Research Project. Research on Risk Communication on Drug Adverse Reactions in Public and Health Care Professionals, Tokyo.
29. The Uppsala Monitoring Centre (1997) Effective Communications in Pharmacovigilance-The Erice Declaration. http://who-umc.org/graphics/24752.pdf. Accessed Febuary 22 2012.
30. The US Food and Drug Administration (2009) CDER Health Information Survey. http://www.fda.gov/. Accessed November 30 2009.
31. The US Food and Drug Administration (2011) Draft Guidance for Industry Medication Guides-Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS).
32. Urushihara H, Doi Y, Arai M, Matsunaga T, Fujii Y, Iino N, Kawamura T, Kawakami K (2011) Oseltamivir prescription and regulatory actions vis-a-vis abnormal behavior risk in Japan: drug utilization study using a nationwide pharmacy database. PloS One 6(12):e28483. doi:10.1371/journal.pone.0028483.
33. Waller PC, Evans SJ, Beard K (2006) Drug safety and the media. Br J Clin Pharmacol 61(2):123-126. doi:10.1111/j.1365-2125.2005.02528.x.
34. Weatherby LB, Walker AM, Fife D, Vervaet P, Klausner MA (2001) Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of 'Dear Doctor' letters. Pharmacoepidemiol Drug Saf 10(3):211-218. doi:10.1002/pds.592 [doi].